Vulvovaginal atrophy: Current and future therapies

Journal of Sexual Medicine

Volumn 7, Issue 3, 2010, Pages 1042-1050

  Ibe, Comfort ^a   Simon, James A ^a  

^a GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Menopausal symptoms; Post Menopausal urogenital atrophy; Vaginal atrophy; Vulvar atrophy

Indexed keywords

ANTIESTROGEN; CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; LASOFOXIFENE; LUBRICATING AGENT; OSPEMIFENE; PLACEBO; PRASTERONE; RALOXIFENE; TAMOXIFEN;

ARTICLE; BREAST CANCER; BREAST TENDERNESS; CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DYSPAREUNIA; ESTROGEN DEFICIENCY; FEAR; FOOD AND DRUG ADMINISTRATION; HUMAN; LOW DRUG DOSE; NATIONAL HEALTH ORGANIZATION; OSTEOPOROSIS; POSTMENOPAUSE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; UNSPECIFIED SIDE EFFECT; UTERUS BLEEDING; VAGINA ATROPHY; VAGINAL DRYNESS; VAGINAL PRURITUS; VAGINITIS; VENOUS THROMBOEMBOLISM;

EID: 77950807123     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2009.01692.x     Document Type: Article

References (57)

1. Ettinger B, Hait H, Reape K, Shu H. Measuring symptom relief in studies of vaginal and vulvar atrophy: The most bothersome symptom approach. Menopause 2008, 15:885-9.
2. Mehta A, Bachmann G. Vulvovaginal complaints. Clin Obstet Gynecol 2008, 51:549-55.
3. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. Menopause 2007, 14:355-69. North American Menopause Society
4. Nachtigall L, Nachtigall M, Goren J, Loewenstein J. Update on vaginal atrophy. Menopause Manag 2005, 17-9. Sep/Oct
5. Bachmann G, Nevadunsky N. Diagnosis and treatment of atrophic vaginitis. Am Fam Physician 2000, 61:3090-6.
6. Castelo-Branco C, Cancelo MJ, Villero J, Nohales F, Juliá MD. Management of post-menopausal vaginal atrophy and atrophic vaginitis. Maturitas 2005, 52S:S46-52.
7. Robinson D, Cardozo L. The role of estrogens in female lower urinary tract dysfunction. Urology 2003, 62:45-51.
8. Goldstein I, Alexander JL. Practical aspects in the management of vaginal atrophy and sexual dysfunction in perimenopausal and postmenopausal women. J Sex Med 2005, 2(3):154-65. suppl
9. Crandall C. Vaginal estrogen preparations: A review of safety and efficacy for vaginal atrophy. J Womens Health 2002, 11:857-77.
10. Caillouette J, Sharp C, Zimmerman G, Roy S. Vaginal pH as a marker for bacterial pathogens and menopausal status. Am J Obstet Gynecol 1997, 176:1270-7.
11. Iosif CS, Batra S, Ek A, Astedt B. Estrogen receptors in the human female lower urinary tract. Am J Obstet Gynecol 1981, 141:817-20.
12. Bergman A, Karram MM, Bhati NN. Changes in urethral cytology following estrogen administration. Gynecol Obstet Invest 1990, 29:211-3.
13. Nachtigall LE. Comparative study: Replens versus local estrogen in menopausal women. Fertil Steril 1994, 61:178-80.
14. Van der Laak J, de Bie L, de Leeuw H, de Wilde P, Hanselaar G. The effect of Replens on vaginal cytology in the treatment of postmenopausal atrophy: Cytomorphology versus computerized cytometry. J Clin Pathol 2002, 55:446-51.
15. Long CY, Liu CM, Hsu SC, Wu CH, Wang CL, Tsai EM. A randomized comparative study of the effects of oral and topical estrogen therapy on the vaginal vascularization and sexual function in hysterectomized postmenopausal women. Menopause 2006, 13:737-43.
16. Simon J, Nachtigall L, Gut R, Lang E, Archer D, Utian W. Effective treatment of vaginal atrophy with an ultra-low-dose estradiol vaginal tablet. Obstet Gynecol 2008, 112:1053-60.
17. Cardozo LD, Wise BG, Benness CJ. Vaginal oestradiol for the treatment of lower urinary tract symptoms in post-menopausal women-a double-blind placebo-controlled study. J Obstet Gynecol 2001, 21:383-5.
18. Santen RJ, Pinkerton JV, Conaway M, Ropka M, Wisniewski L, Demers L, Klein K. Treatment of urogenital atrophy with low-dose estradiol: Preliminary results. Menopause 2002, 9:179-87.
19. Cicinelli E. Intravaginal oestrogen and progestin administration: Advantages and disadvantages. Best Pract Res Clin Obstet Gynaecol 2008, 22:391-405.
20. Scarabin P, Oger E, Plu-Bureau G. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003, 362:428-32.
21. Ballagh SA. Vaginal hormone therapy for urogential and menopausal symptoms. Drugs Aging 2004, 21:757-66.
22. Smith RN, Studd JW. Recent advances in hormone replacement therapy. Br J Hosp Med 1993, 49:799-808.
23. Palacios S, Castelo-Branco C, Cancelo MJ, Vázquez F. Low-dose, vaginally administered estrogens may enhance local benefits of systemic therapy in the treatment of urogenital atrophy in postmenopausal women on hormonal therapy. Maturitas 2005, 50:98-104.
24. Suckling JA, Kennedy R, Lethaby A, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Collab 2006, 4. CD001500
25. Eriksen B. A randomized, open, parallel-group study on the preventive effect of an estradiol-releasing vaginal ring (Estring) on recurrent urinary tract infections in postmenopausal women. Am J Obstet Gynecol 1999, 180:1072-9.
26. Casper F, Petri E. Local treatment of urogenital atrophy with an estradiol-releasing vaginal ring: A comparative and a placebo-controlled multicenter study. Vaginal Ring Study Group. Int Urogynecol J Pelvic Floor Dysfunct 1999, 10:171-6.
27. Naessen T, Berglund L, Ulmsten U. Bone loss in elderly women prevented by ultra-low doses of parenteral 17 beta-estradiol. Am J Obstet Gynecol 1997, 177:115-9.
28. Neassen T, Rodriguez-Macias K, Lithell H. Serum lipid profile improved by ultra-low doses of 17 beta-estradiol in elderly women. J Clin Endocrinol Metab 2001, 86:2757-62.
29. Manonai J, Theppisai U, Suthutvoravut S, Udomsubpayakul U, Chittacharoen A. The effect of estradiol vaginal tablet and conjugated estrogen cream on urogenital symptoms in postmenopausal women: A comparative study. J Obstet Gynaecol Res 2001, 27:255-60.
30. Rioux JE, Devlin C, Gelfand MM, Steinberg WM, Hepburn DS. 17b-estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis. Menopause 2000, 7:156-61.
31. Simunic V, Banovic I, Ciglar S, Jeren L, Pavicic Baldani D, Sprem M. Local estrogen treatment in patients with urogential symptoms. Int J Gynecol Obstet 2003, 82:187-97.
32. Dugal R, Hesla K, Sordal T, Aase KH, Lilleeidet O, Wickstrom E. Comparison of usefulness of estradiol vaginal tablets and estriol vagitories for treatment of vaginal atrophy. Acta Obstet Gynecol Scand 2000, 79:293-97.
33. Bachmann G, Lobo RA, Gut R, Nachtigall L, Notelovitz M. Efficacy of low-dose estradiol vaginal tablets in the treatment of atrophic vaginitis: A randomized controlled trial. Obstet Gynecol 2008, 111:67-76.
34. Notelovitz M, Funk S, Nanavati N, Mazzeo M. Estradiol absorption from vaginal tablets in postmenopausal women. Obstet Gynecol 2002, 99:556-62.
35. Highlights of prescribing information for Premarin. http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020216s060lbl.pdf, US Department of Health and Human Services. Food and Drug Administration, Available at: (accessed March 3, 2009
36. Handa VL, Bachus KE, Johnston WW, Robboy SJ, Hammond CB. Vaginal administration of low-dose conjugated estrogens: Systemic absorption and effects on the endometrium. Obstet Gynecol 1994, 84:215-8.
37. Shulman L, Portman D, Lee W, Balu S, Joshi A, Cobden D, Wang Q, Pashos C. A retrospective managed care claims data analysis of medication adherence to vaginal estrogen therapy: Implications for clinical practice. J Womens Health 2008, 17:569-78.
38. Levine K, William R, Hartman K. Vulvovaginal atrophy is strongly associated with female sexual dysfunction among sexually active postmenopausal women. Menopause 2008, 15:661-6.
39. Davis SR, Guay AT, Shifren JL, Mazer NA. Endocrine aspects of female sexual dysfunction. J Sex Med 2004, 1:82-6.
40. Basson R, Brotto LA, Laan E, Redman C, Utian WH. Assessment and management of women's sexual dysfunction: Problematic desire and arousal. J Sex Med 2005, 2:291-300.
41. Nachtigall L. Clinical trial of the estradiol vaginal ring in the U.S. Maturitas 1995, 22:S43-7. suppl
42. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. JAMA 2004, 291:1701-12. Health Women's, Steering Committee
43. Oger E, Scarabin P. Assessment of the risk of venous thromboembolism among users of hormone replacement therapy. Drugs Aging 1999, 14:55-61.
44. Guidance for industry. Estrogen and estrogen/progestin drug products to treat vasomotor symptoms and vulvar and vaginal atrophy symptoms-recommendations for clinical evaluation. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071643.pdf, US Department of Health and Human Services. Food and Drug Administration. Center for Drug Evaluation and Research (CDER), January 2003. Available at: (accessed November 12, 2008
45. Shelly W, Draper M, Krishnan V, Wong M, Jaffe R. Selective estrogen receptor modulators: An update on recent clinical findings. Obstet Gynecol Surv 2008, 63:163-81.
46. Baker V, Leitman D, Jaffe RB. Selective estrogen receptor modulators in reproductive medicine and biology. Obstet Gynecol Surv 2000, 55:S21-47.
47. Simon J, Komi J. Ospemifene, a new SERM, improves the symptoms of vaginal dryness and dyspareunia in postmenopausal women: Results from a pivotal Phase 3 study. Presented at: 12th World Congress on the Menopause. International Menopause Society; Madrid, Spain; May 19-23, 2008
48. Bachmann GA, Gass A, Moffett A, Portman D, Symons J. Lasofoxifene improves symptoms associated with vaginal atrophy [Abstract P-63]. Menopause 2004, 11:63.
49. Portman D, Moffett A, Kerber I, Drosman S, Somayaji V, Lee A. Lasofoxifene, a selective estrogen receptor modulator, improves objective measures of vaginal atrophy [Abstract P-87]. Menopause 2004, 11:675.
50. Bachmann G, Gass M, Kagan R, Moffett A, Barcomb L, Symons J. Lasofoxifene (laso), a next generation selective estrogen response modulator (SERM) improves dyspareunia in postmenopausal women with vaginal atrophy (VA) [Abstract-erratum]. Menopause 2005, 12:238.
51. Goldstein SR, Cummings SR, Eastell R, Ensrud K, Reid DM, Vukicevic S, LaCroix A, Thompson D, Thompson J, Proulx J, Johnson M, Sriram U. Vaginal effects of lasofoxifene: 3-year results from the PEARL Trial. Menopause 2008, 15:1228. abstract
52. Komi J, Lankinen K, Harkonen P, DeGregorio M, Voipio S, Kivinen S, Tuimala R, Vihtamaki T, Vihko K, Ylikorkala O, Erkkola R. Effects of ospemifene and raloxifene on hormonal status, lipids, genital tract, and tolerability in postmenopausal women. Menopause 2005, 12:202-9.
53. Cline JM, Botts S, Lees CJ, Brommage R. Effects of lasofoxifene on the uterus, vagina, and breast in ovariectomized cynomolgu monkeys (Macaca fascicularis). Am J Obstet Gynecol 2008, 199:158.e1-e8.
54. Labrie F, Luu-The V, Labrie C, Bélanger A, Simard J, Lin S, Pelletie G. Endocrine and intracrine sources of androgens in women: Inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr Rev 2003, 24:152-82.
55. Labrie F, Luu-The V, Bélanger A, Lin S, Simard J, Labrie C. Is DHEA a hormone? Starling review. J Endocrinol 2005, 187:169-96.
56. Labrie F, Cusan L, Gomez JL, Côté I, Bérubé R, Bélanger P, Martel C, Labrie C. Effect of intravaginal DHEA on serum DHEA and eleven of its metabolites in postmenopausal women. J Steroid Biochem Mol Biol 2008, 111:178-94.
57. Labrie F, Diamond P, Cusan L, Gomez JL, Bélanger A. Effect of 12-month DHEA replacement therapy on bone, vagina and endometrium in postmenopausal women. J Clin Endocrinol Metab 1997, 82:3498-505.